Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 ФГБОУ ВО «Оренбургский государственный медицинский университет» МЗ РФ; 2 ГБУЗ «Оренбургская областная клиническая психиатрическая больница №1; 3 ГБУЗ «Оренбургская областная клиническая психиатрическая больница №2
Список исп. литературыСкрыть список 1. Sartorius N. Physical illness in people with mental disorders. World Psychiatry 2007; 6:3-4 2. Narvaez, J. M., Twamley, E. W., McKibbin, C. L., Heaton, R. K., & Patterson, T. L. (2008). Subjective and objective quality of life in schizophrenia. Schizophrenia research, 98(1-3), 201–208. https://doi.org/10.1016/j.schres.2007.09.001 3. Uçok, A., & Gaebel, W. (2008). Side effects of atypical antipsychotics: a brief overview. World psychiatry: official journal of the World Psychiatric Association (WPA), 7(1), 58–62. https://doi.org/10.1002/j.2051-5545.2008 .tb00154.x 4. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, “Goldilocks” actions at dopamine receptors. J Clin Psychiatry. 2001; 62:841–842 5. Gettu N, Saadabadi A. Aripiprazole. [Updated 2021 Jan 19]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547739/?report=classic 6. Thomas, J. E., Caballero, J., & Harrington, C. A. (2015). The Incidence of Akathisia in the Treatment of Schizophrenia with Aripiprazole, Asenapine and Lurasidone: A Meta-Analysis. Current neuropharmacology, 13(5), 681–691. https://doi.org/10.2174/1570159x13666150115220221 7. Citrome, L. Cariprazine in Schizophrenia: Clinical Efficacy, Tolerability, and Place in Therapy. Adv Therapy 30, 114–126 (2013). https://doi.org/ 10.1007/s12325-013-0006-7 8. Stahl, S. (2017). Drugs for psychosis and mood: Unique actions at D3, D2, and D1 dopamine receptor subtypes. CNS Spectrums, 22(5), 375-384. doi:10.1017/S1092852917000608 9. Maramai, S., Gemma, S., Brogi, S., Campiani, G., Butini, S., Stark, H., & Brindisi, M. (2016). Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases. Frontiers in neuroscience, 10, 451. https://doi.org/10.3389/fnins.2016.00451 10. Taylor, S. B., Lewis, C. R., & Olive, M. F. (2013). The neurocircuitry of illicit psychostimulant addiction: acute and chronic effects in humans. Substance abuse and rehabilitation, 4, 29–43. https://doi.org/10.2147/SAR.S39684 11. Schwartz JC, Diaz J, Pilon C, Sokoloff P. Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions. Brain Res. Brain Res. Rev. 2000; 31(2–3): 277–287. 12. Mitra S, Mahintamani T, Kavoor AR, Nizamie SH. Negative symptoms in schizophrenia. Industr. Psychiatry J. 2016; 25(2): 135–144 13. Misiak B, Bieńkowski P, Samochowiec J. Cariprazine - a novel antipsychotic drug and its place in the treatment of schizophrenia. Psychiatr Pol. 2018 Dec 29;52(6):971-981. English, Polish. doi: 10.12740/PP/OnlineFirst/80710. Epub 2018 Dec 29. PMID: 30659560. 14. Citrome L. (2018). Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy. Neuropsychiatric disease and treatment, 14, 2563–2577. https://doi.org/ 10.2147/NDT.S159704 15. https://www.washingtonpost.com/health/2020/07/01/coronavirus-autopsies-findings/ 16. Arden, M. A., & Chilcot, J. (2020). Health psychology and the coronavirus (COVID-19) global pandemic: A call for research. British journal of health psychology, 25(2), 231–232. https://doi.org/10.1111/bjhp.12414 17. https://www.kff.org/coronavirus-covid-19/issue-brief/the-implications-of-covid-19-for-mental-health-... 18. Moritz S, Andreou C, Klingberg S, Thoering T, Peters MJ. Assessment of subjective cognitive and emotional effects of antipsychotic drugs. Effect by defect? Neuropharmacology. 2013 Sep; 72:179-86. doi: 10.1016/j.neuropharm.2013.04.039. Epub 2013 May 3. PMID: 23643756. 19. Penn, D. L., Keefe, R. S., Davis, S. M., Meyer, P. S., Perkins, D. O., Losardo, D., & Lieberman, J. A. (2009). The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophrenia research, 115(1), 17–23. https://doi.org/10.1016/ j.schres.2009.08.016 20. Willie Earley, Hua Guo, David Daniel, Henry Nasrallah, Suresh Durgam, Yan Zhong, Mehul Patel, Ágota Barabássy, Balázs Szatmári, György Németh. Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data, Schizophrenia Research, Volume 204, 2019, Pages 282-288, ISSN 0920-9964, https://doi.org/10.1016/j.schres.2018.08.020. 21. Wolfgang Fleischhacker, Silvana Galderisi, István Laszlovszky, Balázs Szatmári, Ágota Barabássy, Károly Acsai, Erzsébet Szalai, Judit Harsányi, Willie Earley, Mehul Patel, György Németh. The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors, European Psychiatry, Volume 58, 2019, Pages 1-9, ISSN 0924-9338, https://doi.org/10.1016/j.eurpsy.2019.01.015. 22. Duric, V., Banasr, M., Franklin, T., Lepack, A., Adham, N., Kiss, B., Gyertyán, I., & Duman, R. S. (2017). Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model. The international journal of neuropsychopharmacology, 20(10), 788–796. https://doi.org/10.1093/ijnp/pyx038 23. Wang, C., Pan, R., Wan, X., Tan, Y., Xu, L., McIntyre, R. S., Choo, F. N., Tran, B., Ho, R., Sharma, V. K., & Ho, C. (2020). A longitudinal study on the mental health of general population during the COVID-19 epidemic in China. Brain, behavior, and immunity, 87, 40–48. https://doi.org/ 10.1016/j.bbi.2020.04.028 24. Mao, L., Jin, H., Wang, M., Hu, Y., Chen, S., He, Q., Chang, J., Hong, C., Zhou, Y., Wang, D., Miao, X., Li, Y., & Hu, B. (2020). Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA neurology, 77(6), 683–690. https://doi.org/10.1001/jamaneurol.2020.1127 25. Chen, T., Wu, D., Chen, H., Yan, W., Yang, D., Chen, G., Ma, K., Xu, D., Yu, H., Wang, H., Wang, T., Guo, W., Chen, J., Ding, C., Zhang, X., Huang, J., Han, M., Li, S., Luo, X., Zhao, J., … Ning, Q. (2020). Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ (Clinical research ed.), 368, m1091. https://doi.org/10.1136/ bmj.m1091 26. Ferrando, S. J., Klepacz, L., Lynch, S., Tavakkoli, M., Dornbush, R., Baharani, R., Smolin, Y., & Bartell, A. (2020). COVID-19 Psychosis: A Potential New Neuropsychiatric Condition Triggered by Novel Coronavirus Infection and the Inflammatory Response?. Psychosomatics, 61(5), 551–555. https://doi.org/10.1016/j.psym.2020.05.012 27. MRI Brain Findings in 126 Patients with COVID-19: Initial Observations from a Descriptive Literature Review. E. Gulko, M.L. Oleksk, W. Gomes, S. Ali, H. Mehta, P. Overby, F. Al-Mufti, A. Rozenshtein. American Journal of Neuroradiology Sep 2020, DOI: 10.3174/ajnr.A6805 28. Choi, Y., & Lee, M. K. (2020). Neuroimaging findings of brain MRI and CT in patients with COVID-19: A systematic review and meta-analysis. European journal of radiology, 133, 109393. https://doi.org/10.1016/j.ejrad. 2020.109393